{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"40.0"},{"groupId":"OG002","value":"29.8"}]}],"title":"No pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1"},{"groupId":"OG001","value":"52.8"},{"groupId":"OG002","value":"47.1"}]}],"title":"There is pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.4"},{"groupId":"OG001","value":"6.4"},{"groupId":"OG002","value":"14.0"}]}],"title":"There is pain and winces"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"},{"groupId":"OG001","value":"0.8"},{"groupId":"OG002","value":"9.1"}]}],"title":"There is pain, winces and withdraws"}],"denoms":[{"counts":[{"groupId":"OG000","value":"131"},{"groupId":"OG001","value":"129"},{"groupId":"OG002","value":"129"}],"units":"Participants"}],"description":"The study physician assessed the most affected joint for tenderness. Tenderness was measured on a 0 - 3 point scale as follows: 0 = no pain, 1 = patient states that \"there is pain\", 2 = patient states \"there is pain and winces\" and 3 = patient states \"there is pain, winces and withdraws\" on palpation or passive movement of the affected study joint.","groups":[{"description":"Patients on this arm received 150 mg subcutaneously (s.c.) at randomization and upon new flare. The doses were provided as pre-filled syringes. The patients were given 3 injections: two placebo and one active drug.","id":"OG000","title":"Canakinumab, Pre-filled Syringes (PFS)"},{"description":"The patients on this arm received 150 mg s.c. at randomization and upon new flare. The doses were provided as lyophilized power and had to be reconstituted with water for injection before application. The patients were given 3 injections: two placebo and one active drug.","id":"OG001","title":"Canakinumab, Lyophilizate (LYO)"},{"description":"The patients on this arm received 40 mg intramuscular (i.m.) at randomization and upon new flare. The patients were given 3 injections: two placebo and one active drug.","id":"OG002","title":"Triamcinolone Acetonide"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set: The Full Analysis Set (FAS) consisted of all patients as randomized that had at least one dose of study drug. Following the intent-to-treat principle, patients were analyzed according to the treatment they were assigned to at randomization.","reportingStatus":"POSTED","timeFrame":"72 hours","title":"Physician's Assessment of Tenderness","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}